Sector News

Monsanto bid may mean Bayer will cut pharma R&D spending

June 1, 2016
Chemical Value Chain

The proposed $62bn merger with agrochemical firm Monsanto would jeopardise Bayer’s pharmaceutical business, according to a BMI Research analyst.

> Read the full article on the in-Pharma Technologist website

By Dan Stanton

Source: in-Pharma Technologist

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 16, 2021

INEOS reduces planned Antwerp investment

Chemical Value Chain

LinkedIn Twitter Xing EmailINEOS has postponed work on the propane dehydrogenation (PDH) unit at its Antwerp, Belgium site, opting to prioritise construction of the cracker, a company spokesperson said on […]

January 10, 2021

TechnipFMC resumes plans to split company

Chemical Value Chain

TechnipFMC says it has resumed activities related to the previous announced separation of the company into two separate pure-play businesses, TechnipFMC and Technip Energies.

January 10, 2021

Solvay’s extended maternity, paternity & co-parent policy goes into effect

Chemical Value Chain

Solvay’s new policy increases maternity leave to 16 weeks. It is now available to any co-parent regardless of gender or sexual orientation; it also includes parents who adopt. The parent employed by Solvay will receive 100% of his or her salary during this leave period.

Send this to a friend